News - Ranbaxy Laboratories

Filter

Current filters:

Ranbaxy Laboratories

Popular Filters

1 to 25 of 55 results

India’s IPAB upholds Pfizer’s Detrol patent

India’s IPAB upholds Pfizer’s Detrol patent

27-03-2014

In a positive development for US drug giant Pfizer, India's Intellectual Property Appellate Board (IPAB)…

Asia-PacificDetrolGenito-urinaryIndiaPatentsPfizerPharmaceuticalRanbaxy Laboratories

Ranbaxy recalls Lipitor generic over dose error

Ranbaxy recalls Lipitor generic over dose error

10-03-2014

India’s largest drugmaker Ranbaxy Laboratories (BSE: 500359) has recalled more than 64,000 bottles…

Atorvastatin CalciumCardio-vascularIndiaLipitorPharmaceuticalRanbaxy LaboratoriesRegulationUSA

Ranbaxy temporarily suspends shipments from Toansa and Dewas plants

25-02-2014

Indian drugmaker Ranbaxy Laboratories has announced in a letter to the Stock Exchange that it has temporarily…

Asia-PacificDaiichi SankyoGenericsIndiaProductionRanbaxy Laboratories

India and the USA need to collaborate

India and the USA need to collaborate

14-02-2014

Here's our take on the week's top stories.

IndiaPharmaceuticalRanbaxy LaboratoriesRegulationUSAWockhardt

Ranbaxy rises on 4th-qtr performance, but can this continue?

Ranbaxy rises on 4th-qtr performance, but can this continue?

05-02-2014

Ranbaxy Laboratories, India’s largest generic drugmaker by sales, saw its shares rise 5.6% to 340 rupees…

Daiichi SankyoFinancialGenericsRanbaxy Laboratories

Another ban by US FDA on a Ranbaxy production facility

Another ban by US FDA on a Ranbaxy production facility

24-01-2014

As if the Indian drug major has not had enough negative news from the US regulator, the US Food and Drug…

Asia-PacificDaiichi SankyoGenericsIndiaNorth AmericaProductionRanbaxy LaboratoriesRegulationUSA

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar

09-01-2014

India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) and EPIRUS Switzerland, a wholly-owned subsidiary…

Anti-Arthritics/RheumaticsBiosimilarsEPIRUS BiopharmaceuticalsGastro-intestinalsIndiainfliximabLicensingRanbaxy LaboratoriesRemicade

Ranbaxy cleared to market branded generic of Aricept in Canada

Ranbaxy cleared to market branded generic of Aricept in Canada

08-01-2014

The Canadian subsidiary of Ranbaxy Laboratories has received approval to manufacture and market RAN-Donepezil…

AriceptCanadaDaiichi SankyoEisaiGenericsNeurologicalNorth AmericaRAN-DonepezilRanbaxy LaboratoriesRegulation

Daiichi Sankyo sales up while Ranbaxy sales decline

Daiichi Sankyo sales up while Ranbaxy sales decline

01-11-2013

Daiichi Sankyo has released results for the fiscal period April 1 to September 30, showing net sales…

Asia-PacificDaiichi SankyoFinancialPharmaceuticalRanbaxy Laboratories

Ban on FDA-regulated drugs from Ranbaxy's Mohali plant

17-09-2013

There was another blow for India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) yesterday (September…

Asia-PacificDaiichi SankyoGenericsNorth AmericaProductionRanbaxy LaboratoriesRegulation

Ranbaxy 2nd-qtr sales fall 18%; reports loss

08-08-2013

India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) reported second-quarter 2013 financial results,…

FinancialGenericsRanbaxy Laboratories

Leading Indian drugmakers eye pharma production in Russia

08-07-2013

Several top Indian drugmakers and suppliers, including Dr Reddy's (NYSE: RDY), Ranbaxy (BSE: 500359),…

Asia-PacificAurobindo PharmaCiplaDr Reddy's LaboratoriesEuropeGenericsProductionRanbaxy Laboratories

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Ranbaxy highlights its actions on improved business and quality assurance

23-05-2013

Indian drugmaker Ranbaxy Laboratories (BSE: 500359), whose US subsidiary was the subject of the biggest…

Daiichi SankyoGenericsManagementProductionRanbaxy LaboratoriesRegulation

US DoJ says Ranbaxy pleads guilty and agrees to pay $500 million in settlements

14-05-2013

In the largest drug safety settlement to date with a generic drug manufacturer, Ranbaxy USA, a subsidiary…

Asia-PacificDaiichi SankyoFinancialGenericsLegalNorth AmericaProductionRanbaxy LaboratoriesRegulation

Ranbaxy 1st-qtr 2013 earnings plunge 90% as sales fall 34%

08-05-2013

India's largest pharma company Ranbaxy Laboratories (BSE: 500359), which is majority owned by Japan's…

FinancialGenericsRanbaxy Laboratories

Daiichi Sankyo and Ranbaxy to launch branded generics in Brazil

21-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority (64%)-owned Indian affiliate Ranbaxy…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

Daiichi Sankyo sets out five-year plan to overcome Olmetec patent expiry

25-03-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has announced a new five-year Business Plan, which will…

Daiichi SankyoFinancialolmesartanOlmetecPatentsPharmaceuticalRanbaxy Laboratories

Ranbaxy in deal with Alembic to market bioequivalent Pristiq in USA

05-03-2013

The US subsidiary of India's largest drugmaker, Ranbaxy Laboratories (AB: BO), which is majority owned…

Alembic PharmaceuticalsDaiichi SankyoGenericsLicensingMarkets & MarketingNeurologicalNorth AmericaPatentsPfizerPristiqRanbaxy Laboratories

India's Ranbaxy posts 23% sales growth for 2012

26-02-2013

India's largest drugmaker Ranbaxy Laboratories (AB: BO) yesterday reported financial results for 2012,…

FinancialGenericsRanbaxy Laboratories

Indian pharmaceuticals market led by Ranbaxy in terms of revenue

31-01-2013

The Indian pharmaceutical market is the world's third-largest in terms of volume and stands 14th in terms…

Asia-PacificBioconBiotechnologyGenericsMarkets & MarketingPanacea BiotecPharmaceuticalRanbaxy LaboratoriesSerum Institute of India

Daiichi Sankyo and Ranbaxy combine business operations in Thailand

16-01-2013

Japanese pharma major Daiichi Sankyo (TYO: 4568) and its 64%-owned affiliate Ranbaxy Laboratories (AB:…

Asia-PacificDaiichi SankyoGenericsManagementMarkets & MarketingPharmaceuticalRanbaxy Laboratories

Ranbaxy Labs' Absorica debuts in USA

27-11-2012

Indian drugmaker Ranbaxy Laboratories (AB: BO), which is majority owned by Japan's Daiichi Sankyo, said…

AbsoricaCipher PharmaceuticalsDaiichi SankyoDermatologicalsGalephar Pharmaceutival ResearchGenericsMarkets & MarketingNorth AmericaPharmaceuticalRanbaxy Laboratories

1 to 25 of 55 results

Back to top